Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an oral tablet for oral use. It selectively dilates cerebral vessels to prevent vasospasm, helping patients who have experienced a subarachnoid hemorrhage and reduce the risk of delayed neurological deficits.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with established quality systems and regulatory approvals across the European Union and other markets. Our distribution network ensures timely delivery and compliance with local import requirements.

Nimodipine is a cerebral vasodilator used to manage vascular complications after subarachnoid hemorrhage.

Subarachnoid hemorrhage: prevention of cerebral vasospasm. Cerebral vasospasm: reduction of vessel constriction. Delayed cerebral ischemia: lowering incidence after hemorrhage. Neurological recovery: support of cerebral blood flow. Neurovascular protection: mitigation of calcium‑mediated injury.

Nimodipine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache may occur. - Dizziness: sensation of light‑headedness or vertigo. - Nausea: occasional gastrointestinal upset. - Flushing: transient warmth or redness of the skin. - Hypotension: mild drop in blood pressure, usually asymptomatic.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure reduction requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Neutropenia: significant reduction in white blood cells.

When prescribing Nimodipine, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular monitoring: observe blood pressure and heart rate regularly. - Liver function: assess hepatic enzymes before initiation and during therapy. - Renal impairment: adjust use in patients with severe kidney dysfunction. - Drug interactions: review concomitant calcium channel blockers or CYP3A4 inhibitors. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Nimodipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase nimodipine plasma levels, risking toxicity. - Concurrent use with other vasodilators: can cause excessive hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce therapeutic effect. - Antihypertensive agents: additive blood pressure lowering. - Beta‑blockers: may enhance bradycardia. - Diuretics: potential electrolyte imbalance.